HRP20160329T1 - Monovalentne smjese za vezivanje sa cd28 i metode uporabe - Google Patents
Monovalentne smjese za vezivanje sa cd28 i metode uporabe Download PDFInfo
- Publication number
- HRP20160329T1 HRP20160329T1 HRP20160329TT HRP20160329T HRP20160329T1 HR P20160329 T1 HRP20160329 T1 HR P20160329T1 HR P20160329T T HRP20160329T T HR P20160329TT HR P20160329 T HRP20160329 T HR P20160329T HR P20160329 T1 HRP20160329 T1 HR P20160329T1
- Authority
- HR
- Croatia
- Prior art keywords
- variable domain
- immunoglobulin variable
- antibody
- antibody containing
- disease
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 19
- 102000018358 immunoglobulin Human genes 0.000 claims 19
- 239000003446 ligand Substances 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
Claims (14)
1. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu, naznačeno time, što se vezuje za CD28 i uključuje aminokiseline sa sekvencom navedenom u SEQ ID NO:543 (1h-239-891; D70C).
2. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 1, naznačeno time, što se formatira tako da mu se produži in vivo poluživot.
3. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 2, naznačeno time, što formatiranje podrazumijeva vezivanje antitijela koje sadrži jednu imunoglobulinsku varijabilnu domenu za polietilen-glikol (PEG), reakcijom PEGilacije.
4. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 3, naznačeno time, što je PEG vezan preko cisteinske ili lizinske rezidue; ili gdje PEG ima oko 10 do oko 50 kD; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima hidrodinamičku veličinu od najmanje oko 24 kDa; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima hidrodinamičku veličinu od najmanje oko 200 kDa; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima tα-poluživot od oko 15 sekundi do oko 12 sati; ili gdje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ima tβ-poluživot od oko 12 sati do oko 744 sata.
5. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 3, naznačeno time, što je antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu vezano za razgranati PEG od 40 kDa.
6. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 3, naznačeno time, što je antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu vezano za linearni PEG od 40 kDa.
7. Dvojno specifični ligand, naznačen time, što uključuje antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz bilo kojeg od zahtjeva 1 do 6 i jednu varijabilnu domenu koji ima vezujuću aktivnost za antigen različit od CD28.
8. Dvojno specifični ligand iz zahtjeva 7, naznačen time, što je drugi antigen površinski antigen antigen-prezentujuće stanice ili površinski antigen T-stanice; ili gdje je drugi antigen citokin.
9. Nukleinska kiselina, naznačena time, što kodira antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu prema bilo kojem od zahtjeva 1 do 2, ili dvojno specifični ligand prema zahtjevu 7 ili 8.
10. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu prema bilo kojem od zahtjeva 1 do 6 ili dvojno specifični ligand prema zahtjevu 7 ili 8, naznačeni time, što se koriste za liječenje pacijenta, pri čemu pacijent ima ili je pod rizikom dobijanja imunske bolesti.
11. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ili dvojno specifični ligand za uporabu prema zahtjevu 10, naznačeni time, što je imunska bolest autoimunska bolest ili bolest u svezi sa kalemom.
12. Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ili dvojno specifični ligand za uporabu prema zahtjevu 11, naznačeni time, što se spomenuta bolest u svezi sa kalemom bira iz grupe koja se sastoji od odbacivanja alokalmea, odbacivanja ksenokalemskog transplanta i bolesti kalema protiv domaćina; ili gdje se spomenuta autoimunska bolest bira iz grupe koja se sastoji od sustavnog eritemskog lupusa, multiple skleroze, reumatoidnog artritisa, dijabetesa, psorijaze, skleroderme, Sjögren-ovog sindroma, ateroskleroze, upalne bolesti crijeva, Crohn-ove bolesti i ulcerativnog kolitisa.
13. Farmaceutska smjesa, naznačena time, što uključuje terapijski efikasnu količinu antitijela koje sadrži jednu imunoglobulinsku varijabilnu domenu iz bilo kojeg od zahtjeva 1 do 6 ili dvojno specifični ligand prema zahtjevu 7 ili 8, i farmaceutski prihvatljivi nosač.
14. Farmaceutska smjesa iz zahtjeva 13, naznačena time, što uključuje još i imunosupresivno/imunomodulatorno i/ili antiinflamatorno sredstvo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8207808P | 2008-07-18 | 2008-07-18 | |
| US16212109P | 2009-03-20 | 2009-03-20 | |
| PCT/US2009/050985 WO2010009391A1 (en) | 2008-07-18 | 2009-07-17 | Compositions monovalent for cd28 binding and methods of use |
| EP09790582.2A EP2321352B1 (en) | 2008-07-18 | 2009-07-17 | Compositions monovalent for cd28 binding and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160329T1 true HRP20160329T1 (hr) | 2016-04-22 |
Family
ID=41226147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160329TT HRP20160329T1 (hr) | 2008-07-18 | 2016-04-01 | Monovalentne smjese za vezivanje sa cd28 i metode uporabe |
| HRP20190966TT HRP20190966T1 (hr) | 2008-07-18 | 2019-05-28 | Monovalentne smjese za vezivanje sa cd28 i metode upotrebe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190966TT HRP20190966T1 (hr) | 2008-07-18 | 2019-05-28 | Monovalentne smjese za vezivanje sa cd28 i metode upotrebe |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8168759B2 (hr) |
| EP (2) | EP2700651B1 (hr) |
| JP (3) | JP5675608B2 (hr) |
| KR (2) | KR101660057B1 (hr) |
| CN (2) | CN105936648B (hr) |
| AR (1) | AR072571A1 (hr) |
| AU (1) | AU2009270726B2 (hr) |
| CA (1) | CA2731220C (hr) |
| CL (2) | CL2011000117A1 (hr) |
| CO (1) | CO6341641A2 (hr) |
| CY (1) | CY1121796T1 (hr) |
| DK (2) | DK2321352T3 (hr) |
| EA (1) | EA024585B1 (hr) |
| ES (2) | ES2562629T3 (hr) |
| HK (1) | HK1155178A1 (hr) |
| HR (2) | HRP20160329T1 (hr) |
| HU (2) | HUE029982T2 (hr) |
| IL (2) | IL210413A (hr) |
| LT (1) | LT2700651T (hr) |
| ME (1) | ME02396B (hr) |
| MX (1) | MX2011000501A (hr) |
| NZ (1) | NZ590343A (hr) |
| PE (2) | PE20140852A1 (hr) |
| PL (2) | PL2700651T3 (hr) |
| PT (2) | PT2700651T (hr) |
| RS (2) | RS54675B1 (hr) |
| SI (2) | SI2700651T1 (hr) |
| SM (1) | SMT201600090B (hr) |
| TW (2) | TWI450725B (hr) |
| WO (1) | WO2010009391A1 (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2365000A3 (en) | 2005-05-18 | 2013-01-16 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
| PE20140852A1 (es) | 2008-07-18 | 2014-07-14 | Bristol Myers Squibb Co | Composiciones monovalentes para union a cd28 |
| US20110097339A1 (en) * | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| DK2401373T3 (da) * | 2009-02-25 | 2013-10-21 | Nextera As | Signalsekvens-uafhængig pix fag-display |
| FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
| HUE039677T2 (hu) | 2010-02-18 | 2019-01-28 | Ose Immunotherapeutics | Humanizált anti-CD28-ellenanyagok |
| EP2361935A1 (en) * | 2010-02-18 | 2011-08-31 | TcL Pharma | Anti-CD28 humanized antibodies |
| EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JP5768022B2 (ja) * | 2012-03-19 | 2015-08-26 | 株式会社東芝 | メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法 |
| WO2014120916A1 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
| BR112016014824A2 (pt) * | 2013-12-27 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para purificar anticorpo que tem ponto isoelétrico baixo |
| CA2943177A1 (en) * | 2014-03-19 | 2015-09-24 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40l |
| AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
| CN106794255A (zh) * | 2014-09-30 | 2017-05-31 | 百时美施贵宝公司 | 使用针对cd28的域抗体治疗系统性红斑狼疮的方法 |
| WO2017160975A1 (en) | 2016-03-16 | 2017-09-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| JP7474240B2 (ja) | 2018-08-03 | 2024-04-24 | ブリストル－マイヤーズ スクイブ カンパニー | 抗薬物抗体を検出するための方法 |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3938397A1 (en) * | 2019-03-14 | 2022-01-19 | Biond Biologics Ltd. | Small shedding blocking agents |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| US20230041599A1 (en) * | 2019-12-02 | 2023-02-09 | Biond Biologics Ltd. | Use of mmp inhibition |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| BR112022014667A2 (pt) * | 2020-01-29 | 2022-09-20 | Inhibrx Inc | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| WO2022031695A1 (en) * | 2020-08-04 | 2022-02-10 | Exelixis, Inc. | Pd-l1 binding agents and uses thereof |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4399229A2 (en) * | 2021-09-06 | 2024-07-17 | Biond Biologics Ltd. | Cd28 shedding blocking agents |
| TW202400659A (zh) * | 2022-05-04 | 2024-01-01 | 美商詹努克斯治療有限公司 | 經腫瘤活化之靶向ｃｄ２８及ｐｄ－ｌ１之多特異性抗體及其使用方法 |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
| WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024077118A2 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839295A (en) | 1984-06-08 | 1989-06-13 | Pierce Chemical Company | Measurement of protein using bicinchoninic acid |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| EP0814778B1 (de) | 1995-03-10 | 2001-06-13 | Roche Diagnostics GmbH | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| AU8800598A (en) | 1997-06-20 | 1999-01-04 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| JP2002512182A (ja) | 1998-04-20 | 2002-04-23 | ジェンザイム・コーポレーション | ポリマーブレンドから蛋白質のドラックデリバリー |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| EP1179013A1 (en) | 1999-05-14 | 2002-02-13 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
| US20020006403A1 (en) * | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
| PT1345969E (pt) * | 2000-12-26 | 2010-11-17 | Inst Nat Sante Rech Med | Anticorpos anti-cd28 |
| US20080095774A1 (en) | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| EP1419179B1 (en) | 2001-08-10 | 2010-03-03 | Aberdeen University | Antigen binding domains from fish |
| WO2003031611A2 (en) | 2001-10-05 | 2003-04-17 | Cangene Corporation | Phagemid display system |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| ZA200702427B (en) * | 2004-09-17 | 2008-12-31 | Domantis Ltd | Compositions monovalent for CD40L binding and methods of use |
| GB0614093D0 (en) | 2006-07-14 | 2006-08-23 | Bae Systems Plc | Deployable antenna system |
| AU2007331672A1 (en) * | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| PE20140852A1 (es) * | 2008-07-18 | 2014-07-14 | Bristol Myers Squibb Co | Composiciones monovalentes para union a cd28 |
| RU2011110459A (ru) | 2008-08-21 | 2012-09-27 | Октафарма АГ (CH) | Рекомбинантно полученный человеческий фактор viii и ix |
| CA2943177A1 (en) * | 2014-03-19 | 2015-09-24 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40l |
| CN106794255A (zh) * | 2014-09-30 | 2017-05-31 | 百时美施贵宝公司 | 使用针对cd28的域抗体治疗系统性红斑狼疮的方法 |
-
2009
- 2009-07-17 PE PE2014000192A patent/PE20140852A1/es not_active Application Discontinuation
- 2009-07-17 RS RS20160200A patent/RS54675B1/en unknown
- 2009-07-17 PT PT13185422T patent/PT2700651T/pt unknown
- 2009-07-17 RS RS20190631A patent/RS58904B1/sr unknown
- 2009-07-17 PL PL13185422T patent/PL2700651T3/pl unknown
- 2009-07-17 ES ES09790582.2T patent/ES2562629T3/es active Active
- 2009-07-17 KR KR1020117003660A patent/KR101660057B1/ko active IP Right Grant
- 2009-07-17 US US12/505,166 patent/US8168759B2/en active Active
- 2009-07-17 SI SI200931964T patent/SI2700651T1/sl unknown
- 2009-07-17 HU HUE09790582A patent/HUE029982T2/en unknown
- 2009-07-17 CN CN201610344002.1A patent/CN105936648B/zh active Active
- 2009-07-17 PL PL09790582T patent/PL2321352T3/pl unknown
- 2009-07-17 EA EA201100239A patent/EA024585B1/ru not_active IP Right Cessation
- 2009-07-17 DK DK09790582.2T patent/DK2321352T3/en active
- 2009-07-17 TW TW098124305A patent/TWI450725B/zh not_active IP Right Cessation
- 2009-07-17 ES ES13185422T patent/ES2730727T3/es active Active
- 2009-07-17 EP EP13185422.6A patent/EP2700651B1/en active Active
- 2009-07-17 ME MEP-2016-76A patent/ME02396B/me unknown
- 2009-07-17 KR KR1020167025702A patent/KR101791372B1/ko active IP Right Grant
- 2009-07-17 NZ NZ590343A patent/NZ590343A/xx unknown
- 2009-07-17 DK DK13185422.6T patent/DK2700651T3/da active
- 2009-07-17 SI SI200931383T patent/SI2321352T1/sl unknown
- 2009-07-17 TW TW101147598A patent/TW201336510A/zh unknown
- 2009-07-17 EP EP09790582.2A patent/EP2321352B1/en active Active
- 2009-07-17 AU AU2009270726A patent/AU2009270726B2/en not_active Ceased
- 2009-07-17 WO PCT/US2009/050985 patent/WO2010009391A1/en active Application Filing
- 2009-07-17 HU HUE13185422A patent/HUE045249T2/hu unknown
- 2009-07-17 MX MX2011000501A patent/MX2011000501A/es active IP Right Grant
- 2009-07-17 CN CN2009801358711A patent/CN102159590A/zh active Pending
- 2009-07-17 LT LTEP13185422.6T patent/LT2700651T/lt unknown
- 2009-07-17 JP JP2011518935A patent/JP5675608B2/ja active Active
- 2009-07-17 PE PE2011000053A patent/PE20110385A1/es active IP Right Grant
- 2009-07-17 AR ARP090102734A patent/AR072571A1/es active IP Right Grant
- 2009-07-17 PT PT97905822T patent/PT2321352E/pt unknown
- 2009-07-17 CA CA2731220A patent/CA2731220C/en not_active Expired - Fee Related
-
2010
- 2010-12-30 IL IL210413A patent/IL210413A/en active IP Right Grant
-
2011
- 2011-01-18 CL CL2011000117A patent/CL2011000117A1/es unknown
- 2011-02-15 CO CO11017973A patent/CO6341641A2/es active IP Right Grant
- 2011-09-02 HK HK11109298.7A patent/HK1155178A1/zh not_active IP Right Cessation
-
2012
- 2012-03-09 US US13/415,914 patent/US9085629B2/en active Active
- 2012-03-09 US US13/416,033 patent/US8454959B2/en active Active
- 2012-08-31 CL CL2012002428A patent/CL2012002428A1/es unknown
-
2014
- 2014-12-24 JP JP2014261305A patent/JP5876134B2/ja active Active
-
2015
- 2015-06-16 US US14/740,709 patent/US9908937B2/en active Active
-
2016
- 2016-01-20 JP JP2016009024A patent/JP6058833B2/ja active Active
- 2016-03-29 SM SM201600090T patent/SMT201600090B/xx unknown
- 2016-04-01 HR HRP20160329TT patent/HRP20160329T1/hr unknown
-
2017
- 2017-03-21 IL IL251320A patent/IL251320B/en active IP Right Grant
-
2018
- 2018-01-12 US US15/870,121 patent/US10919965B2/en active Active
-
2019
- 2019-05-28 HR HRP20190966TT patent/HRP20190966T1/hr unknown
- 2019-07-09 CY CY20191100722T patent/CY1121796T1/el unknown
-
2020
- 2020-11-02 US US17/086,565 patent/US12012452B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160329T1 (hr) | Monovalentne smjese za vezivanje sa cd28 i metode uporabe | |
| JP2011528551A5 (hr) | ||
| Abramson | Monoclonal antibodies for the treatment of multiple myeloma: an update | |
| Taubert et al. | Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated | |
| EP3538559A1 (en) | Recombinant pmhc class ii molecules | |
| HRP20180941T1 (hr) | Protutijela protiv il-17 | |
| KR20180011135A (ko) | 지속 치료를 위한 나노입자 조성물 | |
| HRP20171278T1 (hr) | Sastavi s nanočesticama za proizvodnju regulacijskih t-stanica i liječenje autoimunih bolesti kao i ostalih kroničnih upalnih stanja | |
| HRP20150330T1 (hr) | Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga | |
| Uppaluri et al. | Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody | |
| JP2010523582A5 (hr) | ||
| CN105814083A (zh) | 嵌合抗原受体t细胞开关和其用途 | |
| JP2010042007A5 (hr) | ||
| JP2017527272A5 (hr) | ||
| Kato et al. | Adipose tissue-derived stem cells suppress acute cellular rejection by TSG-6 and CD44 interaction in rat kidney transplantation | |
| König et al. | Tregalizumab–a monoclonal antibody to target regulatory T cells | |
| DK2343320T3 (da) | Anti-gitr-antistoffer og anvendelser deraf | |
| IL268058B2 (en) | Compositions and methods for depleting cd137 plus cells | |
| JP2019518460A5 (hr) | ||
| Lappas et al. | Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation | |
| WO2009149382A3 (en) | Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells | |
| Lykhopiy et al. | IL-2 immunotherapy for targeting regulatory T cells in autoimmunity | |
| Flanagan et al. | Immunogenicity of protein-N-(2-hydroxypropyl) methacrylamide copolymer conjugates in A/J and B10 mice | |
| Day et al. | Mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosis | |
| JP7335821B2 (ja) | 免疫調節機能を有するＦａｓＬ操作を受けた生体材料 |